RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 AFFINITY
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 21
SP 9
OP 10
DO 10.1177/1559897715599367
UL http://mdc.sagepub.com/content/15/21/9.2.abstract
AB A pivotal open-label trial of rVIII-SingleChain in adolescents and adults with hemophilia A was conducted. Pharmacokinetic results indicate that, when compared with octocog alfa, this agent has lower clearance, a greater area under the curve, and a longer half-life. rVIII-SingleChain is efficacious and well tolerated when it is used prophylactically or on demand.